MX2015016143A - Peptidos de angiotensina para tratar el sindrome de marfan y transtornos relacionados. - Google Patents

Peptidos de angiotensina para tratar el sindrome de marfan y transtornos relacionados.

Info

Publication number
MX2015016143A
MX2015016143A MX2015016143A MX2015016143A MX2015016143A MX 2015016143 A MX2015016143 A MX 2015016143A MX 2015016143 A MX2015016143 A MX 2015016143A MX 2015016143 A MX2015016143 A MX 2015016143A MX 2015016143 A MX2015016143 A MX 2015016143A
Authority
MX
Mexico
Prior art keywords
marfan
marfan syndrome
related disorders
angiotensin
related disorder
Prior art date
Application number
MX2015016143A
Other languages
English (en)
Inventor
Richard Franklin
Original Assignee
Tarix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarix Pharmaceuticals Ltd filed Critical Tarix Pharmaceuticals Ltd
Publication of MX2015016143A publication Critical patent/MX2015016143A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente invención proporciona, entre otras cosas, métodos para tratar el síndrome de Marfan y/o un trastorno relacionado con el síndrome de Marfan incluyendo la administración a un sujeto que padece o es susceptibles al síndrome de Marfan y/o un trastorno relacionado con el síndrome de Marfan, un péptído de angiotensina (1-7); en algunas modalidades, el péptido de angiotensina (1-7) se administra en una dosis eficaz de manera periódica en un intervalo de administración tal que al menos un síntoma o característica del síndrome de Marfan y/o un trastorno relacionado con el síndrome de Marfan es reducido en intensidad, severidad, duración o frecuencia o ha demorado su inicio.
MX2015016143A 2013-05-24 2014-05-22 Peptidos de angiotensina para tratar el sindrome de marfan y transtornos relacionados. MX2015016143A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361827271P 2013-05-24 2013-05-24
PCT/US2014/039141 WO2014190152A1 (en) 2013-05-24 2014-05-22 Angiotensin peptides in treating marfan syndrome and related disorders

Publications (1)

Publication Number Publication Date
MX2015016143A true MX2015016143A (es) 2016-03-31

Family

ID=51934150

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016143A MX2015016143A (es) 2013-05-24 2014-05-22 Peptidos de angiotensina para tratar el sindrome de marfan y transtornos relacionados.

Country Status (11)

Country Link
US (3) US9107870B2 (es)
EP (1) EP3003345A4 (es)
JP (1) JP2016520592A (es)
KR (1) KR20160016872A (es)
CN (1) CN105451756A (es)
AU (1) AU2014268524A1 (es)
BR (1) BR112015028788A2 (es)
CA (1) CA2912635A1 (es)
MX (1) MX2015016143A (es)
RU (1) RU2015147241A (es)
WO (1) WO2014190152A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3350200A4 (en) 2015-09-18 2019-03-27 Wake Forest University Health Services ANGIOTENSIN ANALOGUES (1-7) AND ASSOCIATED METHODS
CA2914601A1 (en) * 2015-12-11 2017-06-11 Wake Forest University Health Sciences Angiotensin-(1-7) analogs and methods relating thereto
CN109666729A (zh) * 2019-01-29 2019-04-23 四川省人民医院 一种马凡综合征筛查试剂盒
WO2024052343A1 (en) * 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Trem-2 agonists for the treatment of marfan syndrome

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
US5182264A (en) * 1986-03-07 1993-01-26 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
US20020168761A1 (en) 2000-01-24 2002-11-14 Gour Barbara J. Peptidomimetic modulators of cell adhesion
EP0937103B1 (en) 1996-07-12 2007-11-28 McGILL UNIVERSITY Compounds and methods for modulating cell adhesion
YU78601A (sh) 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
US20030078190A1 (en) * 2001-05-25 2003-04-24 Weinberg Marc S. Methods for tissue protection using highly effective inhibition of the renin-angiotensin system
ES2526705T3 (es) * 2005-10-25 2015-01-14 The Johns Hopkins University Métodos y composiciones para el tratamiento de síndrome de Marfan y trastornos asociados
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
BRPI0800585B8 (pt) 2008-02-13 2021-05-25 Univ Minas Gerais composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)
ES2393455T3 (es) * 2008-09-12 2012-12-21 Charité-Universitátsmedizin Berlin (Charité) Uso de un agonista del receptor Ang-(1-7) en lesiones pulmonares agudas
CL2008003736A1 (es) 2008-12-15 2009-05-29 Univ Pontificia Catolica Chile Uso de angiotensina (1-9) para preparar un medicamento, util para prevenir, revertir y/o disminuir el remodelado cardiovascular, pulmonar, renal y/o cerebral.
JP2014525439A (ja) * 2011-08-30 2014-09-29 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ ナトリウム利尿ポリペプチド
WO2013090833A1 (en) * 2011-12-16 2013-06-20 Tarix Pharmaceuticals Ltd. Angiotensins for treatment of fibrosis
EP2819687A4 (en) * 2012-02-10 2015-09-30 Tarix Pharmaceuticals Ltd COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL VASCULAR DISEASE
DK2967049T3 (da) * 2013-03-15 2020-12-07 Univ Southern California Metoder, forbindelser og sammensætninger til behandlingen af angiotensin relaterede sygdomme

Also Published As

Publication number Publication date
JP2016520592A (ja) 2016-07-14
CN105451756A (zh) 2016-03-30
AU2014268524A1 (en) 2015-12-03
US20160038560A1 (en) 2016-02-11
KR20160016872A (ko) 2016-02-15
US20180050079A1 (en) 2018-02-22
US20150031634A1 (en) 2015-01-29
RU2015147241A (ru) 2017-06-29
BR112015028788A2 (pt) 2017-09-19
US9107870B2 (en) 2015-08-18
EP3003345A1 (en) 2016-04-13
CA2912635A1 (en) 2014-11-27
EP3003345A4 (en) 2017-03-01
WO2014190152A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
MX2018004947A (es) Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados.
MX2023008368A (es) Uso de antagonista de il-33 o un antagonista de il-4r en la fabricacion de un medicamento para tratar enfermedades o trastornos inflamatorios.
EA201690581A1 (ru) ЛЕЧЕНИЕ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
MX2016005237A (es) Terapia de acido ribonucleico mensajero para la deficiencia de argininosuccinato sintetasa.
NZ774222A (en) Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
MX2015009631A (es) Folistatina en el tratamiento de distrofia muscular de duchenne.
MX2015011434A (es) Partículas inmunomodificadoras para el tratamiento de la inflamación.
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
MY176031A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
MY169210A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EA201990425A1 (ru) Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
MX2015016143A (es) Peptidos de angiotensina para tratar el sindrome de marfan y transtornos relacionados.
MX2015003968A (es) Angiotensina en el tratamiento de condiciones cerebrales.
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
NZ629828A (en) Methods for the treatment of b cell-mediated inflammatory diseases
EA201691020A1 (ru) Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина"
EA201690855A1 (ru) Эндоглиновые пептиды для лечения фиброзных заболеваний
PE20151526A1 (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod
EA201692155A1 (ru) МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
EA201890257A1 (ru) Комбинированное лечение, предусматривающее введение 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридинов

Legal Events

Date Code Title Description
HH Correction or change in general